Barry Schechter, MD
Ophthalmology · Boynton Beach, FLNPI 1487716494
Payments from drug & device makers
Across 689 payments — averaging $496.16 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Sun Pharmaceutical Industries Inc.$122K
- Bausch & Lomb Americas Inc.$75K
- Johnson & Johnson Surgical Vision, Inc.$50K
- Bausch & Lomb, A Division Of Bausch Health US, LLC$32K
- Amgen$24K
- Eyevance Pharmaceuticals LLC$15K
- plus $24K from 24 others
What the payments were for
- Consulting fees$12,7665%
- Speaking & faculty fees$198,14075%
- Travel & lodging$13,8445%
- Food & beverage$20,4418%
- Education$18,8177%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Sun Pharmaceutical Industries Inc. | 163 | $121,938 |
| Bausch & Lomb Americas Inc. | 119 | $74,521 |
| Johnson & Johnson Surgical Vision, Inc. | 40 | $49,891 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 63 | $31,876 |
| Amgen(2 entities) | 49 | $24,348 |
| Eyevance Pharmaceuticals LLC | 19 | $15,019 |
| ANI Pharmaceuticals, Inc. | 22 | $12,569 |
| Glaukos Corporation | 13 | $2,774 |
| NEW World Medical,inc. | 29 | $2,377 |
| Harrow Eye, LLC | 21 | $1,714 |
| AbbVie(2 entities) | 43 | $1,120 |
| Tarsus Pharmaceuticals, Inc. | 26 | $641 |
| Dompe US, Inc. | 13 | $571 |
| Novartis | 10 | $421 |
| Alcon | 8 | $298 |
| Dr.reddy's Laboratories,inc. | 1 | $276 |
| Ocular Therapeutix, Inc. | 12 | $236 |
| Aerie Pharmaceuticals, Inc. | 5 | $199 |
| Rxsight Inc | 4 | $198 |
| Kala Pharmaceuticals, Inc. | 8 | $179 |
| Shire North American Group Inc | 3 | $167 |
| Ivantis, Inc | 2 | $137 |
| Oyster Point Pharma, Inc. | 4 | $109 |
| Apellis Pharmaceuticals, Inc. | 2 | $58 |
| Rayner Intraocular Lenses Limited | 2 | $54 |
| Regeneron Healthcare Solutions, Inc. | 3 | $54 |
| Biotissue Holdings Inc. | 1 | $34 |
| Sight Sciences, Inc. | 2 | $34 |
| Neurotech Pharmaceuticals, Inc. | 1 | $20 |
| Halozyme Inc | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- CEQUA$84,353
- MIEBO$61,304
- XIIDRA$58,379
- LOTEMAX SM$28,633
- TEPEZZA$23,735
- PURIFIED CORTROPHIN GEL$12,075
- Tobradex ST$8,846
- BROMSITE$5,840
- LOTEMAX$4,563
- Flarex$4,159
- Tecnis Symfony IOL$2,132
- Zerviate$1,948
- VEVYE$1,200
- Kahook Dual Blade$1,063
- Clearpath$1,063
- Ahmed Glaucoma Valve$1,063
- Streamline$1,063
- BLINK NUTRITEARS$850
- Via360$730
- Tecnis IOL$683
How this compares
$341,852 in reported general payments places this provider in the 95th percentile of 1,405 ophthalmology providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OxervateCenegermin-Bkbj | 12 | $445,391 |
| RestasisCyclosporine | 382 | $428,942 |
| CequaCyclosporine | 119 | $115,903 |
| MieboPerfluorohexyloctane/Pf | 89 | $76,729 |
| LumiganBimatoprost | 155 | $61,763 |
| Lotemax SmLoteprednol Etabonate | 215 | $57,659 |
| XiidraLifitegrast | 44 | $48,642 |
| Cyclosporine | 83 | $43,644 |
| XdemvyLotilaner | 22 | $40,999 |
| RocklatanNetarsudil Mesylat/Latanoprost | 75 | $30,069 |
| VevyeCyclosporine | 37 | $28,279 |
| TyrvayaVarenicline Tartrate | 28 | $17,308 |
| CombiganBrimonidine Tartrate/Timolol | 34 | $11,608 |
| VyzultaLatanoprostene Bunod | 22 | $10,862 |
| Loteprednol Etabonate | 58 | $9,398 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieRestasis, Lumigan, Combigan, Alphagan P | $1,120 | $508,300586 claims |
| Dompe US, Inc.Oxervate | $571 | $445,39112 claims |
| Bausch & Lomb Americas Inc.Miebo, Xiidra, Vyzulta | $74,521 | $136,232155 claims |
| Sun Pharmaceutical Industries Inc.Cequa, Bromsite | $121,938 | $121,131140 claims |
| Bausch & Lomb, A Division Of Bausch Health US, LLCLotemax Sm, Loteprednol Etabonate | $31,876 | $67,057273 claims |
| Tarsus Pharmaceuticals, Inc.Xdemvy | $641 | $40,99922 claims |
| Aerie Pharmaceuticals, Inc.Rocklatan, Rhopressa | $199 | $37,94789 claims |
| Harrow Eye, LLCVevye | $1,714 | $28,27937 claims |
| Oyster Point Pharma, Inc.Tyrvaya | $109 | $17,30828 claims |
| NovartisIlevro | $421 | $6,95419 claims |
| AlconSimbrinza | $298 | $4,83822 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,405 ophthalmology providers in Florida.
Other ophthalmology in Boynton Beach
- Sirtaz SibiaBoynton Beach$445K
- David EichenbaumSt Petersburg$34.4M
- Robert RadenDelray Beach$7.8M
- Carl DanzigPompano Beach$5.3M
- Bruce SegalDelray Beach$4.7M
- Cathleen McCabeBradenton$4.6M
- Ivan SunerTampa$3.7M
- Sunir JoshiFt Lauderdale$3.7M
- Harold BrooksTallahassee$3.5M
- Matthew CunninghamOrlando$2.9M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.